scholarly journals Serum Hepatocyte Growth Factor Predicts Ventricular Remodeling Following Myocardial Infarction

2002 ◽  
Vol 66 (11) ◽  
pp. 1003-1007 ◽  
Author(s):  
Takeshi Soeki ◽  
Yoshiyuki Tamura ◽  
Hisanori Shinohara ◽  
Koichi Sakabe ◽  
Yukiko Onose ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Ventricular Remodeling ◽  
Hepatocyte Growth

scholarly journals Hepatocyte growth factor intervention to reduce myocardial injury and improve cardiac function on diabetic myocardial infarction rats

2020 ◽  
Vol 64 (s2) ◽  
Author(s):  
Zaiyong Zhang ◽  
Cheng Long ◽  
Yufeng Guan ◽  
Mingcai Song
Keyword(s):  
Myocardial Infarction ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Cardiac Function ◽  
Ventricular Remodeling ◽  
Myocardial Cell ◽  
Diabetic Rats ◽  
Control Group ◽  
Myocardial Apoptosis ◽  
Hepatocyte Growth

Acute myocardial infarction (AMI) is recognized to be a severe threat to people’s health conditions and life quality. The accumulation of hepatocyte growth factor (HGF) in ischemic myocardium has been observed in both processes of experimental ischemia and reperfusion (I/R) and permanent coronary artery occlusion. The aim of the study was to investigate the effect of HGF on myocardial cell apoptosis, ventricular remodeling and cardiac function after myocardial infarction (MI) in diabetic rats, and to explore whether the effect is mediated by HGF/c-Met signaling pathway. MI significantly increases LVWI and RVWI and myocardial apoptotic index, and up-regulates the expression of HGF and c-Met at mRNA and protein levels in MI control group. The LVWI and RVWI, and myocardial apoptosis were reduced by treatment with HGF, which also increased the myocardial cell viability and the expression of HGF and c-Met. In summary, HGF significantly attenuates myocardial apoptosis and improves cardiac function after AMI in diabetic rats by further enhancing the activation of HGF/c-Met pathway.

scholarly journals Exercise-Induced Hepatocyte Growth Factor Production in Patients After Acute Myocardial Infarction

2004 ◽  
Vol 68 (4) ◽  
pp. 304-307 ◽  
Author(s):  
Satoshi Yasuda ◽  
Yoichi Goto ◽  
Hiroshi Takaki ◽  
Yasuhide Asaumi ◽  
Takeshi Baba ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Factor Production ◽  
Growth Factor Production ◽  
Exercise Induced ◽  
Hepatocyte Growth

Increased Circulating Hepatocyte Growth Factor in the Early Stage of Acute Myocardial Infarction

1996 ◽  
Vol 221 (2) ◽  
pp. 391-395 ◽  
Author(s):  
Akira Matsumori ◽  
Yutaka Furukawa ◽  
Tetsuo Hashimoto ◽  
Koh Ono ◽  
Tetsuo Shioi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Early Stage ◽  
Hepatocyte Growth

scholarly journals Gene Therapy with Hepatocyte Growth Factor Improves Left Ventricular Systolic Function After Myocardial Infarction: A Systematic Review and Meta-analysis of Pig Models

2020 ◽  
Author(s):  
Chong Du ◽  
Xiao-Wen Chen ◽  
Ze-Mu Wang ◽  
Hao-Yu Meng ◽  
Ya-Fei Li ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gene Therapy ◽  
Heart Disease ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Meta Analysis ◽  
Capillary Density ◽  
Left Ventricular ◽  
Intramyocardial Injection ◽  
Hepatocyte Growth

Abstract Background: Hepatocyte growth factor (HGF) is an angiogenic cytokine which can promote angiogenesis and inhibit fibrosis. Previous studies have shown that HGF may have significant therapeutic effects on ischaemic diseases, such as ischaemic heart disease and peripheral arterial occlusive disease. Due to insufficient clinical study evidence, we conducted a quantitative meta-analysis of HGF therapy in pigs with myocardial infarction (MI) to provide more reliable evidence for the feasibility and effectiveness of HGF therapy for MI patients. We also analysed the efficacy and characteristics of different gene therapy vectors and drug delivery routes.Methods: PubMed, EMBASE, and the China National Knowledge Infrastructure were searched for randomised studies that corresponded to our subject. The search terms included (hepatocyte growth factor OR HGF) AND (heart failure OR HF OR myocardial infarction OR MI OR AMI OR coronary heart disease OR CHD). The retrieved articles were screened strictly according to the inclusion criteria. The endpoints were the left ventricular ejection fraction (LVEF) and capillary density in the ischaemic regions in the model pigs.Results: A total of nine studies were eventually included in this meta-analysis. Our analysis showed that LVEF (with mean difference [MD]:9.73, 95%CI :8.70, 10.76, P < 0.00001) and capillary density (MD:79.98, 95%CI :24.58,135.39, P=0.005) in the HGF group were significantly higher than those in the control group several weeks after HGF treatment. Further analysis showed that there was no statistically significant difference in the improvement of LVEF caused by intracoronary adenovirus5-mediated HGF (Ad5-HGF) gene transfer and intramyocardial plasmid HGF injection (12.63±3.2 vs 9.4±1.09, P=0.06), while intramyocardial injection of plasmid HGF had a stronger angiogenic capacity than intramyocardial administration of Ad5-HGF and HGF in hydrogel (117.34±27.82 vs 26.45±22.11 vs 11.50±5.28, P＜0.00001).Conclusions: HGF therapy can effectively promote angiogenesis and recovery of cardiac function and is a promising cardiac repair method. Intracoronary Ad5 vector transfer and intramyocardial injection of plasmid vectors can be used as effective means of gene therapy, and hydrogel as a vector also has potential applications.

Sign in / Sign up

Export Citation Format

Share Document